Abhilasha Borad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Abhilasha Borad has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Abdul Azim
Rutgers Robert Wood Johnson Medical School
1 shared publication Ali Ibrahim
The State University of New Jersey
1 shared publication- Ang Li
Section of Hematology-Oncology, Baylor College of Medicine , Houston, TX
1 shared publication Danielle Guffey
Institute for Clinical & Translational Research, Baylor College of Medicine Houston Texas USA
1 shared publication- Hamnah Saeed
Ernest Mario School of Pharmacy at Rutgers, The State University of New Jersey, NJ, USA
1 shared publication Hanqing Shang
Division of Hematology‐Oncology Keck School of Medicine of University of Southern California Los Angeles California USA
1 shared publication
Latest Publications
- Open Access
- 27 March 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (6) , 1379-1387
The Impact of Anticoagulation in Patients With Isolated Cancer‐Associated Splanchnic Vein Thrombosis: A Dual‐Center Cohort Study
Data to guide management of isolated bland cancer‐associated splanchnic vein thrombosis (CA‐SpVT) are limited. We aimed to assess the role of anticoagulation (AC) and bleeding and thrombosis in patients with CA‐SpVT. We conducted a dual‐center retrospective cohort study of adults with incident, isolated, bland CA‐SpVT from 2011 to 2020. The primary outcome was major bleeding (MB); other outcomes included usual‐site venous thromboembolism (VTE) recurrence and progression/recanalization of CA‐SpVT. Time‐to‐event outcomes were analyzed with weighted Cox models adjusting for cancer type, stage, SpVT location, and whether symptomatic. For SpVT recanalization/progression, differences were estimated using weighted average treatment effects (ATEs). After excluding tumor thrombus, we included 437 patients with notable characteristics of median age 60 years, portal vein thrombosis (81.2%), and underlying hepatocellular cancer (35.9%). Of these, 29.5% received therapeutic AC. At 6 months, there were 11.9% MB and 6.4% incident usual‐site VTE events. Among 308 patients with follow‐up imaging, the 1‐year thrombus progression rate was 19.8% and thrombus recanalization was 28.6%. In the adjusted analysis, there were numerically higher rates of MB with AC (adjusted hazard ratio [aHR] 1.93, 95% confidence interval [CI] 0.97–3.87) and no significant difference in the incidence of VTE (aHR 1.41, 95% CI 0.56–3.51). AC was associated with significantly higher likelihood of venous recanalization (ATE +24% 95% CI 13%–35%) and significantly lower likelihood of thrombus progression (ATE –14% 95% CI –23% to −5%). In patients with isolated bland CA‐SpVT, AC was associated with thrombus recanalization and limited thrombus progression; effects were offset by a potentially higher risk of MB.
- 27 March 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (6) , 1379-1387
Open AccessThe Impact of Anticoagulation in Patients With Isolated Cancer‐Associated Splanchnic Vein Thrombosis: A Dual‐Center Cohort Study
Data to guide management of isolated bland cancer‐associated splanchnic vein thrombosis (CA‐SpVT) are limited. We aimed to assess the role of anticoagulation (AC) and bleeding and thrombosis in patients with CA‐SpVT. We conducted a dual‐center retrospective cohort study of adults with incident, isolated, bland CA‐SpVT from 2011 to 2020. The primary outcome was major bleeding (MB); other outcomes included usual‐site venous thromboembolism (VTE) recurrence and progression/recanalization of CA‐SpVT. Time‐to‐event outcomes were analyzed with weighted Cox models adjusting for cancer type, stage, SpVT location, and whether symptomatic. For SpVT recanalization/progression, differences were estimated using weighted average treatment effects (ATEs). After excluding tumor thrombus, we included 437 patients with notable characteristics of median age 60 years, portal vein thrombosis (81.2%), and underlying hepatocellular cancer (35.9%). Of these, 29.5% received therapeutic AC. At 6 months, there were 11.9% MB and 6.4% incident usual‐site VTE events. Among 308 patients with follow‐up imaging, the 1‐year thrombus progression rate was 19.8% and thrombus recanalization was 28.6%. In the adjusted analysis, there were numerically higher rates of MB with AC (adjusted hazard ratio [aHR] 1.93, 95% confidence interval [CI] 0.97–3.87) and no significant difference in the incidence of VTE (aHR 1.41, 95% CI 0.56–3.51). AC was associated with significantly higher likelihood of venous recanalization (ATE +24% 95% CI 13%–35%) and significantly lower likelihood of thrombus progression (ATE –14% 95% CI –23% to −5%). In patients with isolated bland CA‐SpVT, AC was associated with thrombus recanalization and limited thrombus progression; effects were offset by a potentially higher risk of MB.
- Open Access
- 16 September 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e220
Comparing contamination rates in paired blood culture sets with a single-time stamp vs multiple-time stamps
This retrospective analysis compares the recovery rate of commensal organisms in two sets of blood cultures with a single-time stamp (STS) versus ones with multiple-time stamps (MTS) in an academic tertiary center. Rates in which both sets were positive for commensals were numerically higher in STS versus MTS.
- 16 September 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e220
Open AccessComparing contamination rates in paired blood culture sets with a single-time stamp vs multiple-time stamps
This retrospective analysis compares the recovery rate of commensal organisms in two sets of blood cultures with a single-time stamp (STS) versus ones with multiple-time stamps (MTS) in an academic tertiary center. Rates in which both sets were positive for commensals were numerically higher in STS versus MTS.
- 1 July 2020
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 26 (6) , 1475-1481
Age demographics of subjects enrolled in interventional phase 3 multiple myeloma clinical trials
The mean and median ages of diagnosis of multiple myeloma range from 70 to 73 years old, with 63% of patients being over the age of 65. Phase 3 clinical trials are designed to study efficacy in the target disease population and are meant to have the most representative subject pool. The purpose of this review is to identify the age demographic of subjects participating in interventional phase 3 clinical trials that aim to treat multiple myeloma and to determine if they encompass the true age demographic of the disease. To complete this review, a search of phase 3 multiple myeloma research trials with reported results was conducted on clinicaltrials.gov, a national, publicly available resource listing clinical trials. Reported mean or median ages of subjects were identified for each trial, and adjusted averages of these values were calculated. Data from 81 clinical trials were assessed, with 42 trials reporting an average mean age of 65.78 years and 15 trials reporting an average median age of 63.29 years. Based on these results, it was determined that the clinical trials reported in this study enrolled patients that were younger than the true age demographic of the disease. There is an unmet need in research in the older population of patients with multiple myeloma, and this may hinder the generalizability and utility of clinical trial results.
- 1 July 2020
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 26 (6) , 1475-1481
Age demographics of subjects enrolled in interventional phase 3 multiple myeloma clinical trials
The mean and median ages of diagnosis of multiple myeloma range from 70 to 73 years old, with 63% of patients being over the age of 65. Phase 3 clinical trials are designed to study efficacy in the target disease population and are meant to have the most representative subject pool. The purpose of this review is to identify the age demographic of subjects participating in interventional phase 3 clinical trials that aim to treat multiple myeloma and to determine if they encompass the true age demographic of the disease. To complete this review, a search of phase 3 multiple myeloma research trials with reported results was conducted on clinicaltrials.gov, a national, publicly available resource listing clinical trials. Reported mean or median ages of subjects were identified for each trial, and adjusted averages of these values were calculated. Data from 81 clinical trials were assessed, with 42 trials reporting an average mean age of 65.78 years and 15 trials reporting an average median age of 63.29 years. Based on these results, it was determined that the clinical trials reported in this study enrolled patients that were younger than the true age demographic of the disease. There is an unmet need in research in the older population of patients with multiple myeloma, and this may hinder the generalizability and utility of clinical trial results.